Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS. Tan DS, et al. Among authors: kaye sb. Clin Cancer Res. 2009 Apr 1;15(7):2269-80. doi: 10.1158/1078-0432.CCR-08-2403. Epub 2009 Mar 17. Clin Cancer Res. 2009. PMID: 19293255
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.
Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, El-Bahrawy M, Gore ME, Gabra H, Kaye SB, Ashworth A, Reis-Filho JS. Tan DS, et al. Among authors: kaye sb. Clin Cancer Res. 2011 Mar 15;17(6):1521-34. doi: 10.1158/1078-0432.CCR-10-1688. Clin Cancer Res. 2011. PMID: 21411445
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME. Tan DS, et al. Among authors: kaye sb. J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955455
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series.
Agarwal R, Gourley C, Perren TJ, Reed N, Parkin DE, Carty K, Rustin GJ, Gabra H, Paul J, Gore ME, Kaye SB; Scottish Gynecological Cancers Trials Group. Agarwal R, et al. Among authors: kaye sb. Eur J Cancer. 2010 Jul;46(11):2020-6. doi: 10.1016/j.ejca.2010.03.006. Epub 2010 Apr 13. Eur J Cancer. 2010. PMID: 20395128 Clinical Trial.
738 results